Navigation Links
Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Date:5/30/2008

and myalgia (2.1% vs. 0.4%).

Type 2 Diabetes: In clinical trials, the adverse reactions observed in greater than or equal to 2% of patients -- and more commonly with Welchol than placebo - regardless of investigator assessment of causality were constipation (8.7% vs. 2.0%), nasopharyngitis (4.1% vs. 3.6%) dyspepsia (3.9% vs. 1.4%), hypoglycemia (3.0% vs. 2.3%), nausea (3.0% vs. 1.4%) and hypertension (2.8% vs. 1.6%).

Post-marketing experience: Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International Normalized Ratio (INR) has been reported in patients receiving warfarin concomitantly with Welchol.

Welchol is Pregnancy Category B.

For more information on Welchol, call 877-4-DSPROD (877-437-7763), or go to the Welchol web site at http://www.Welchol.com.

About Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., one of Japan's leading pharmaceutical companies and a global leader in pharmaceutical innovation whose roots date back to 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world. The primary focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit http://www.dsus.com.

References:


'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
2. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
3. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
4. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
7. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
8. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
11. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008).... 1 Vical Incorporated (...$1.0 million milestone payment from Merck & Co...hase I clinical trial of an investigational plasmi... is based on Vical,s DNA gene delivery technology ... (hTERT). hTERT is the subject of separate license...
(Date:11/28/2008)...Nov. 28 Eli Lilly and Co...al New Drug Application (sNDA) from,the U.S. Food...loxetine HCl),for the management of chronic pain....irst half of 2009, adding data from a recently com...ain of the knee. , The decision does not af...
(Date:11/26/2008)... to 406 Subjects , , FRANKLIN, Mass., Nov. ... Bulletin Board: PLCSF) announced today that it ha...ug Administration (FDA) for its U.S. pivotal trial...Guard System(TM) and associated therapy in the pr... , The FDA also approved PLC,s request to ex...
(Date:11/25/2008)...CISCO, Calif., Nov. 25 Proteolix, ...f novel therapeutics that target,protein degradat...day,announced that data from two ongoing Phase 2 ...a will be presented at the upcoming 50th Annual Me.... Carfilzomib is the first in a new class,of spe...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Longs Drugs Partners With Google on the Launch of Google Health 19817 1Longs Drugs Partners With Google on the Launch of Google Health 19817 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 1bioMETRX Expands Engineering and Manufacturing Capabilities 3366 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 1TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 2TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 4Greener offices make happier employees 19812 1Greener offices make happier employees 19812 2
...itional Findings Reported on Glucose Homeostasis E...ne 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,... doses of the,investigational compound dapaglifloz...ansporter 2 (SGLT2) administered alone or,concomit...tes, no,discontinuations due to adverse events and...
...VILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/...hree Phase I trials,studying REP8839, a novel topi...vity against major skin pathogens including,methic...he Phase I,trials show that topically applied REP8...th low systemic exposure, or drug,absorption into ...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4
(Date:12/1/2008)...S, Dec. 2 While many Ame...ic challenges including rising costs of,basic nec...ess Scripts,(Nasdaq: ESRX ) has expanded Rx Out...escription medicines. , (Logo: http://www...OGO ) , Lower-income consumers can now rece...
(Date:12/1/2008)...O New research reveals that computed tomography (...y, has the potential to screen for two diseases at...hich commonly affect adults over age 50. Results o...meeting of the Radiological Society of North Ameri...to screening for colorectal cancer, we were able t...
(Date:12/1/2008)... Warren Presents Award, Engages with President on ...ome and Abroad During Saddleback Civil Forum on Gl...ire/ -- President George W. Bush was honored on th...he "International Medal of PEACE" given by Dr. Ric...uring the Saddleback Civil Forum on Global Health....
(Date:12/1/2008)...ls shut down and stop dividing when their DNA is d... so as to prevent damaged DNA from leading to unre...r, a new study, published in this week,s issue of ...ut down they also spew proteins into their surroun...s up conditions that support the development of ag...
Breaking Medicine News(10 mins):Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 2Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 3Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 4Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2
...d the glass jars over the slight incisions on his ... In the ensuing vacuum , the thick dark blood slow...ners. "The Assyrians, the Chinese and the ancient...ing to draw out the corrupt blood," said Hajam as ...
...arch groups described how they had quickly fallen ...ng pregnant making them feel stressed which they ...iving. They also reported becoming anxious that se...e. As the months passed and the couples did not f...
...sing weight to get into shape for her new movie 'K...a 'super-in-shape reporter' in her new movie , had...mits that she didn't like it one bit, and insists ... hardest things she's ever had to do, especially a...
... team of researchers has found evidence that peopl...mon sleep disorder called restless legs syndrome ...loping hypertension. RLS is a common and debilita...ffects the lives of tens of millions of people wor...
Other Medicine News:Health News:Ancient Healing Technique Gains New Popularity in Iraq 2Health News:Research Shows How Women Deal With the Stress When Trying for a Baby! 2Health News:Research Shows How Women Deal With the Stress When Trying for a Baby! 3Health News:Boffins Find Link Between Common Sleep Disorder and Hypertension 2
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: